Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 13, 2015 - Issue 12
Submit an article Journal homepage
653
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Antiarrhythmic drugs in pregnancy

Jennifer M. WrightCardiovascular Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USACorrespondence[email protected]
,
Richard L. PageCardiovascular Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
&
Michael E. FieldCardiovascular Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Pages 1433-1444 | Published online: 29 Oct 2015

References

  • Papers of special note have been highlighted as:
  • * of interest
  • ** of considerable interest
  • Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol. 1997;79(8):1061–1064.
  • Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol. 2006;97(8):1206–1212.
  • Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol. 1995;76(10):675–678.
  • Food and Drug Administration, HHS. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014;79(233):72063–72103.
  • Committee for Medicinal Products for Human Use. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data [Internet]. London: European Medicines Agency; 2005; p. 1–21. [cited 2015 Oct]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf
  • Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf. 1999;20(1):85–94.
  • Meyer J, Lackner JE, Schochet SS. Paroxysmal tachycardia in pregnancy. JAMA. 1930;94(24):1901–1904.
  • Domula M, Weissbach G, Lenk H, et al. [Effect of drug therapy during pregnancy on the clotting potential of the newborn]. Zentralbl Gynakol. 1977;99(8):473–481.
  • Rotmensch HH, Elkayam U, Frishman W. Antiarrhythmic drug therapy during pregnancy. Ann Intern Med. 1983;98(4):487–497.
  • Wong RD, Murthy AR, Mathisen GE, et al. Treatment of severe falciparum malaria during pregnancy with quinidine and exchange transfusion. Am J Med. 1992;92(5):561–562.
  • Hill LM, Malkasian GD Jr. The use of quinidine sulfate throughout pregnancy. Obstet Gynecol. 1979;54(3):366–368.
  • Guntheroth WG, Cyr DR, Mack LA, et al. Hydrops from reciprocating atrioventricular tachycardia in a 27-week fetus requiring quinidine for conversion. Obstet Gynecol. 1985;66(3 Suppl):29S–33S.
  • Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. 1995;130(4):871–876.
  • Kleinman CS, Copel JA, Weinstein EM, et al. Treatment of fetal supraventricular tachyarrhythmias. J Clin Ultrasound. 1985;13(4):265–273.
  • Allen NM, Page RL. Procainamide administration during pregnancy. Clin Pharm. 1993;12(1):58–60.
  • Shaxted EJ, Milton PJ. Disopyramide in pregnancy: a case report. Curr Med Res Opin. 1979;6(1):70–72.
  • Tadmor OP, Keren A, Rosenak D, et al. The effect of disopyramide on uterine contractions during pregnancy. Am J Obstet Gynecol. 1990;162(2):482–486.
  • Abbi M, Kriplani A, Singh B. Preterm labor and accidental hemorrhage after disopyramide therapy in pregnancy. A case report. J Reprod Med. 1999;44(7):653–655.
  • Kuhnert BR, Knapp DR, Kuhnert PM, et al. Maternal, fetal, and neonatal metabolism of lidocaine. Clin Pharmacol Ther. 1979;26(2):213–220.
  • Juneja MM, Ackerman WE, Kaczorowski DM, et al. Continuous epidural lidocaine infusion in the parturient with paroxysmal ventricular tachycardia. Anesthesiology. 1989;71(2):305–308.
  • Menon KP, Mahapatra RK. Paroxysmal ventricular tachycardia associated with Bell’s palsy in a teenager at late pregnancy. Angiology. 1984;35(8):534–536.
  • Pagès H, de la Gastine B, Quedru-Aboane J, et al. Intoxication néonatale à la lidocaïne après analgésie par bloc des nerfs honteux: à propos de trois observations. J De Gynécologie Obstétrique Biol De La Reprod. 2008;37(4):415–418.
  • Timmis AD, Jackson G, Holt DW. Mexiletine for control of ventricular dysrhythmias in pregnancy. Lancet. 1980;2(8195 pt 1):647–648.
  • Gregg AR, Tomich PG. Mexilitene use in pregnancy. J Perinatol. 1988;8(1):33–35.
  • Wagner X, Jouglard J, Moulin M, et al. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J. 1990;119(3, Part 1):700–702.
  • Ahmed K, Issawi I, Peddireddy R. Use of flecainide for refractory atrial tachycardia of pregnancy. Am J Crit Care. 1996;5(4):306–308.
  • Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011;124(16):1747–1754.

*A retrospective comparison of digoxin, flecainide and sotalol for the treatment of fetal tachycardia in >100 patients. No significant adverse fetal events were seen except for one episode of fetal bradycardia with maximal dose flecainide and sotalol used concomitantly

  • Ebenroth ES, Cordes TM, Darragh RK. Second-line treatment of fetal supraventricular tachycardia using flecainide acetate. Pediatr Cardiol. 2001;22(6):483–487.

*A retrospective chart review evaluating the efficacy and safety of flecainide for the treatment of fetal supraventricular tachycardia (SVT) after digoxin failure in 37 pregnancies. The study found increased conversion rates with addition of flecainide without any significant fetal adverse events with either drug exposure

  • Frohn-Mulder IM, Stewart PA, Witsenburg M. The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia. Prenat Diagn. 1995;15(13):1297–1302.
  • Rasheed A, Simpson J, Rosenthal E. Neonatal ECG changes caused by supratherapeutic flecainide following treatment for fetal supraventricular tachycardia. Heart. 2003;89(4):470.
  • Brunozzi LT, Meniconi L, Chiocchi P, et al. Propafenone in the treatment of chronic ventricular arrhythmias in a pregnant patient. Br J Clin Pharmacol. 1988;26(4):489–490.
  • Libardoni M, Piovan D, Busato E, et al. Transfer of propafenone and 5-OH-propafenone to foetal plasma and maternal milk. Br J Clin Pharmacol. 1991;32(4{Libardoni, 1991 #17}):527–528.
  • Davis RL, Eastman D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20(2):138–145.
  • Lennestal R, Otterblad Olausson P, Kallen B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol. 2009;65(6):615–625.
  • Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012;2(4):e001185. doi:10.1136/bmjopen-2012-001185

*A retrospective study reviewing 2459 patients exposed to β-blockers during pregnancy and found an association between β-blocker use and increased risk for small for gestational age newborns, preterm labor and perinatal mortality when compared to the unexposed population

  • Ersbøll AS, Hedegaard M, Søndergaard L, et al. Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG Int J Obstetrics Gynaecol. 2014;121(5):618–626.

*Retrospectively evaluated pregnancy outcomes when β-blockers were used for the treatment of maternal heart disease. Despite the presence of maternal heart disease in all patients, β-blockers were associated with an increased risk for low birth weight, particularly if used for a longer duration, compared to the unexposed cohort

  • Wichman K, Ryden G, Karlberg BE. A placebo controlled trial of metoprolol in the treatment of hypertension in pregnancy. Scand J Clin Lab Invest Suppl. 1984;169:90–95.
  • Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12(6):541–547.
  • Lip GY, Beevers M, Churchill D, et al. Effect of atenolol on birth weight. Am J Cardiol. 1997;79(10):1436–1438.
  • Bartalena L, Bogazzi F, Braverman LE, et al. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001;24(2):116–130.
  • Pézard PG, Boussion F, Sentilhes L, et al. Fetal tachycardia: a role for amiodarone as first- or second-line therapy? Arch Cardiovasc Dis. 2008;101(10):619–627.
  • Strasburger JF, Cuneo BF, Michon MM, et al. Amiodarone therapy for drug-refractory fetal tachycardia. Circulation. 2004;109(3):375–379.

*A retrospective evaluation of amiodarone therapy for fetal SVT treatment after digoxin failure in the setting of hydrops. SVT conversion rates were high with amiodarone though nearly one-third of exposed fetuses developed transient fetal hypothyroidism

  • Lomenick JP, Jackson WA, Backeljauw PF. Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol. 2004;24(6):397–399.
  • Magee LA, Downar E, Sermer M, et al. Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol. 1995;172(4 Pt 1):1307–1311.
  • Ovadia M, Brito M, Hoyer GL, et al. Human experience with amiodarone in the embryonic period. Am J Cardiol. 1994;73(4):316–317.
  • O’Hare MF, Leahey W, Murnaghan GA, et al. Pharmacokinetics of sotalol during pregnancy. Eur J Clin Pharmacol. 1983;24(4):521–524.
  • O’Hare MF, Russell CJ, Leahey WJ, et al. Sotalol in the management of hypertension complicating pregnancy [proceedings]. Br J Clin Pharmacol. 1979;8(4):390P–391P.
  • Oudijk MA, Michon MM, Kleinman CS, et al. Sotalol in the treatment of fetal dysrhythmias. Circulation. 2000;101(23):2721–2726.
  • Shah A, Moon-Grady A, Bhogal N, et al. Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias. Am J Cardiol. 2012;109(11):1614–1618.

*A retrospective evaluation of sotalol therapy with or without digoxin for the treatment of fetal SVT. Notably, there were no significant adverse events in the 21 pregnancies reviewed

  • van der Heijden LB, Oudijk MA, Manten GT, et al. Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. Ultrasound Obstet Gynecol. 2013;42(3):285–293.
  • Webster WS, Brown-Woodman PD, Snow MD, et al. Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology. 1996;53(3):168–175.
  • Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001;104(3):292–296.
  • Danielsson C, Brask J, Skold AC, et al. Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism. Cardiovasc Res. 2013;97(1):23–32.
  • Burkart TA, Kron J, Miles WM, et al. Successful termination of atrial flutter by ibutilide during pregnancy. Pacing Clin Electrophysiol. 2007;30(2):283–286.
  • Kockova R, Kocka V, Kiernan T, et al. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol. 2007;18(5):545–547.
  • Marks TA, Terry RD. Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology. 1996;54(3):157–164.
  • Klein V, Repke JT. Supraventricular tachycardia in pregnancy: cardioversion with verapamil. Obstet Gynecol. 1984;63(3 Suppl):16S–18S.
  • Byerly WG, Hartmann A, Foster DE, et al. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991;20(5):552–554.
  • Elkayam UG, Goodwin TM. Adenosine therapy for supraventricular tachcyardia during pregnancy. Am J Cardiol. 1994;75:521–523.

*A retrospective survey to review the safety of adenosine use throughout pregnancy in 32 women. While transient uterine contractions were seen in one patient, no fetal complications were attributed to adenosine

  • Harrison JK, Greenfield RA, Wharton JM. Acute termination of supraventricular tachycardia by adenosine during pregnancy. Am Heart J. 1992;123(5):1386–1388.
  • Hagley MT, Cole PL. Adenosine use in pregnant women with supraventricular tachycardia. Ann Pharmacother. 1994;28(11):1241–1242.
  • Tak T, Berkseth L, Malzer R. A case of supraventricular tachycardia associated with Wolff-Parkinson-White syndrome and pregnancy. WMJ. 2012;111(5):228–232.
  • Hellenkamp K, Weil MB, Aschka C, et al. Fetal heart rate during termination of maternal supraventricular tachycardia with adenosine. Clin Res Cardiol. 2014;103(5):413–416.
  • Dunn JS Jr, Brost BC. Fetal bradycardia after IV adenosine for maternal PSVT. Am J Emerg Med. 2000;18(2):234–235.
  • Afridi I, Moise KJ Jr., Rokey R. Termination of supraventricular tachycardia with intravenous adenosine in a pregnant woman with Wolff-Parkinson-White syndrome. Obstet Gynecol. 1992;80(3 Pt 2):481–483.
  • Canlorbe G, Azria E, Michel D, et al. Preterm labour after adenosine treatment for paroxysmal supraventricular tachycardia during pregnancy, a case report. Ann Fr Anesth Reanim. 2011;30(4):372–374.
  • Hasdemir C, Musayev O, Alkan MB, et al. Termination of idiopathic sustained monomorphic ventricular tachycardia by intravenous adenosine in a pregnant woman. Europace. 2009;11(11):1560–1561.
  • Rogers MC, Willerson JT, Goldblatt A, et al. Serum digoxin concentrations in the human fetus, neonate and infant. N Engl J Med. 1972;287(20):1010–1013.
  • Page RL, Joglar JA, Caldwell MA, et al. ACC/AHA/HRS Guideline for the management of adult patients with supraventricular tachycardia. J Am Cardiol. 2015. doi:10.1016/j.jacc.2015.08.856
  • Li, JM, Nguyen C, Joglar JA, et al. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol. 2008;31(11):538–541.
  • Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429.
  • Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: The task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147–3197.
  • Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979;135(4):485–489.
  • Cuneo BF, Strasburger JF, Yu S, et al. In utero diagnosis of long QT syndrome by magnetocardiography. Circulation. 2013;128(20):2183–2191.
  • Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol. 2010;21(8):877–882.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.